Home › Kanser sa Ovary › Texas › Fort Worth
Pag-aaral pangklinika para sa Kanser sa Ovary sa Fort Worth, TX
Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Fort Worth. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Nagre-recruitPhase 2/3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- START Center for Cancer Research - Texas, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- START Center for Clinical Research, Fort Worth
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Nagre-recruitPhase 2
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Nagre-recruitPhase 3
- Texas Oncology - DFW ( Site 8005), Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Nagre-recruitPhase 2
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Nagre-recruitPhase 3
- Jps Health Network, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Nagre-recruitPhase 1/2
- Start Dfw, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Start - Dfw, Fort Worth
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Nagre-recruitPhase 3
- Texas Oncology - DFW ( Site 8001), Fort Worth
Study of NTB-928 in R/R OC
Nagre-recruitPhase 1
- Start Ccbd, Llc, Fort Worth
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Xencor Investigative Site, Fort Worth
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- USOR Texas Oncology, Fort Worth
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Nagre-recruitPhase 2/3
- Texas Oncology Paris, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Nagre-recruitPhase 1
- START Dallas, Fort Worth
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Nagre-recruitPhase 2
- SCRI - Texas Oncology, Fort Worth
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY69 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA44 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- San Antonio, TX31 pag-aaral
- Cleveland, OH30 pag-aaral
Iba pang pag-aaral sa Fort Worth
- Non-Small Cell Lung Cancer18 pag-aaral
- Kanser ng Endometrium12 pag-aaral
- Kanser sa Suso12 pag-aaral
- Kanser (lahat ng uri)9 pag-aaral
- Kanser sa Prostate9 pag-aaral
- Triple-Negative Breast Cancer7 pag-aaral
- Degenerasyon ng Macula7 pag-aaral
- Ulcerative Colitis7 pag-aaral
- Kanser sa Bato (Renal Cell Carcinoma)7 pag-aaral
- Pagkabigo ng Puso7 pag-aaral
- Metastatic Cancer7 pag-aaral
- Colorectal Cancer7 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.